| Id |
Subject |
Object |
Predicate |
Lexical cue |
| SS1_23074401_3_0 |
346-365 |
expanded |
denotes |
Cancer Care Ontario |
| SS2_23074401_3_0 |
367-370 |
abbr |
denotes |
CCO |
| SS1_23074401_4_0 |
698-741 |
expanded |
denotes |
Provincial Expert Panel on Pharmacogenomics |
| SS2_23074401_4_0 |
743-747 |
abbr |
denotes |
PEPP |
| SS1_23074401_6_0 |
922-957 |
expanded |
denotes |
Technology Assessment Collaborative |
| SS2_23074401_6_0 |
959-964 |
abbr |
denotes |
THETA |
| SS1_23074401_6_1 |
1296-1354 |
expanded |
denotes |
Economic AnalysisEpidermal Growth Factor Receptor Mutation |
| SS2_23074401_6_1 |
1356-1360 |
abbr |
denotes |
EGFR |
| SS1_23074401_6_2 |
1415-1440 |
expanded |
denotes |
Tyrosine Kinase Inhibitor |
| SS2_23074401_6_2 |
1442-1445 |
abbr |
denotes |
TKI |
| SS1_23074401_10_0 |
2006-2023 |
expanded |
denotes |
estrogen-receptor |
| SS2_23074401_10_0 |
2025-2027 |
abbr |
denotes |
ER |
| SS1_23074401_10_1 |
2045-2066 |
expanded |
denotes |
progesterone-receptor |
| SS2_23074401_10_1 |
2068-2070 |
abbr |
denotes |
PR |
| SS1_23074401_11_0 |
2219-2229 |
expanded |
denotes |
lymph node |
| SS2_23074401_11_0 |
2231-2233 |
abbr |
denotes |
LN |
| SS1_23074401_15_0 |
3027-3074 |
expanded |
denotes |
reverse transcription polymerase chain reaction |
| SS2_23074401_15_0 |
3076-3082 |
abbr |
denotes |
RT-PCR |
| SS1_23074401_15_1 |
3087-3119 |
expanded |
denotes |
formalin-fixed paraffin-embedded |
| SS2_23074401_15_1 |
3121-3125 |
abbr |
denotes |
FFPE |
| SS1_23074401_16_0 |
3444-3465 |
expanded |
denotes |
progesterone receptor |
| SS2_23074401_16_0 |
3467-3469 |
abbr |
denotes |
PR |
| SS1_23074401_2_0 |
4543-5450 |
expanded |
denotes |
MBASE, the Cumulative Index to Nursing & Allied Health Literature (CINAHL), the Cochrane Library, and the International Agency for Health Technology Assessment (INAHTA) for studies published from January 1(st), 2006 to March 19(th), 2010. A starting search date of January 1(st), 2006 was because a comprehensive systematic review of Oncotype-DX was identified in preliminary literature searching. This systematic review, by Marchionni et al. (2008), included literature up to January 1(st), 2007. All studies identified in the review by Marchionni et al. as well as those identified in updated literature searching were used to form the evidentiary base of this review. The quality of the overall body of evidence was identified as high, moderate, low or very low according to GRADE methodology.
INCLUSION CRITERIA: Any observational trial, controlled clinical trial, randomized controlled trial (RCT), met |
| SS1_23074401_23_0 |
4554-4608 |
expanded |
denotes |
Cumulative Index to Nursing & Allied Health Literature |
| SS2_23074401_23_0 |
4610-4616 |
abbr |
denotes |
CINAHL |
| SS1_23074401_23_1 |
4649-4702 |
expanded |
denotes |
International Agency for Health Technology Assessment |
| SS2_23074401_23_1 |
4704-4710 |
abbr |
denotes |
INAHTA |
| SS1_23074401_29_0 |
5412-5439 |
expanded |
denotes |
randomized controlled trial |
| SS2_23074401_29_0 |
5441-5444 |
abbr |
denotes |
RCT |
| SS2_23074401_2_0 |
5961-5964 |
abbr |
denotes |
MAS |
| SS1_23074401_36_0 |
6540-6561 |
expanded |
denotes |
disease-free survival |
| SS2_23074401_36_0 |
6563-6566 |
abbr |
denotes |
DFS |
| AE1_23074401_10_0 |
SS1_23074401_10_0 |
SS2_23074401_10_0 |
abbreviatedTo |
estrogen-receptor,ER |
| AE1_23074401_10_1 |
SS1_23074401_10_1 |
SS2_23074401_10_1 |
abbreviatedTo |
progesterone-receptor,PR |
| AE1_23074401_11_0 |
SS1_23074401_11_0 |
SS2_23074401_11_0 |
abbreviatedTo |
lymph node,LN |
| AE1_23074401_15_0 |
SS1_23074401_15_0 |
SS2_23074401_15_0 |
abbreviatedTo |
reverse transcription polymerase chain reaction,RT-PCR |
| AE1_23074401_15_1 |
SS1_23074401_15_1 |
SS2_23074401_15_1 |
abbreviatedTo |
formalin-fixed paraffin-embedded,FFPE |
| AE1_23074401_16_0 |
SS1_23074401_16_0 |
SS2_23074401_16_0 |
abbreviatedTo |
progesterone receptor,PR |
| AE1_23074401_23_0 |
SS1_23074401_23_0 |
SS2_23074401_23_0 |
abbreviatedTo |
Cumulative Index to Nursing & Allied Health Literature,CINAHL |
| AE1_23074401_23_1 |
SS1_23074401_23_1 |
SS2_23074401_23_1 |
abbreviatedTo |
International Agency for Health Technology Assessment,INAHTA |
| AE1_23074401_29_0 |
SS1_23074401_29_0 |
SS2_23074401_29_0 |
abbreviatedTo |
randomized controlled trial,RCT |
| AE1_23074401_2_0 |
SS1_23074401_2_0 |
SS2_23074401_2_0 |
abbreviatedTo |
"MBASE, the Cumulative Index to Nursing & Allied Health Literature (CINAHL), the Cochrane Library, and the International Agency for Health Technology Assessment (INAHTA) for studies published from January 1(st), 2006 to March 19(th), 2010. A starting search date of January 1(st), 2006 was because a comprehensive systematic review of Oncotype-DX was identified in preliminary literature searching. This systematic review, by Marchionni et al. (2008), included literature up to January 1(st), 2007. All studies identified in the review by Marchionni et al. as well as those identified in updated literature searching were used to form the evidentiary base of this review. The quality of the overall body of evidence was identified as high, moderate, low or very low according to GRADE methodology.
INCLUSION CRITERIA: Any observational trial, controlled clinical trial, randomized controlled trial (RCT), met",MAS |
| AE1_23074401_36_0 |
SS1_23074401_36_0 |
SS2_23074401_36_0 |
abbreviatedTo |
disease-free survival,DFS |
| AE1_23074401_3_0 |
SS1_23074401_3_0 |
SS2_23074401_3_0 |
abbreviatedTo |
Cancer Care Ontario,CCO |
| AE1_23074401_4_0 |
SS1_23074401_4_0 |
SS2_23074401_4_0 |
abbreviatedTo |
Provincial Expert Panel on Pharmacogenomics,PEPP |
| AE1_23074401_6_0 |
SS1_23074401_6_0 |
SS2_23074401_6_0 |
abbreviatedTo |
Technology Assessment Collaborative,THETA |
| AE1_23074401_6_1 |
SS1_23074401_6_1 |
SS2_23074401_6_1 |
abbreviatedTo |
Economic AnalysisEpidermal Growth Factor Receptor Mutation,EGFR |
| AE1_23074401_6_2 |
SS1_23074401_6_2 |
SS2_23074401_6_2 |
abbreviatedTo |
Tyrosine Kinase Inhibitor,TKI |
